Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Shares of Trillium Therapeutics jumped above $17 on Aug. 23 on word Pfizer would buy the Canadian drug developer in a $2.3 billion deal.
Trillium Therapeutics Inc is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$17.91|
|52-week range||$5.80 - $20.96|
|50-day moving average||$17.56|
|200-day moving average||$11.37|
|Wall St. target price||$19.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||0.90%|
|1 month (2021-09-27)||1.02%|
|3 months (2021-07-27)||174.27%|
|6 months (2021-04-27)||94.25%|
|1 year (2020-10-27)||41.58%|
|2 years (2019-10-25)||6,548.11%|
|3 years (2018-10-26)||487.21%|
|5 years (2016-10-27)||25.24%|
|Gross profit TTM||$148,000|
|Return on assets TTM||-15.6%|
|Return on equity TTM||-29.91%|
|Market capitalisation||$1.9 billion|
TTM: trailing 12 months
There are currently 2.4 million Trillium Therapeutics shares held short by investors – that's known as Trillium Therapeutics's "short interest". This figure is 14.8% down from 2.8 million last month.
There are a few different ways that this level of interest in shorting Trillium Therapeutics shares can be evaluated.
Trillium Therapeutics's "short interest ratio" (SIR) is the quantity of Trillium Therapeutics shares currently shorted divided by the average quantity of Trillium Therapeutics shares traded daily (recently around 1.9 million). Trillium Therapeutics's SIR currently stands at 1.28. In other words for every 100,000 Trillium Therapeutics shares traded daily on the market, roughly 1280 shares are currently held short.
However Trillium Therapeutics's short interest can also be evaluated against the total number of Trillium Therapeutics shares, or, against the total number of tradable Trillium Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trillium Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Trillium Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.023% of the tradable shares (for every 100,000 tradable Trillium Therapeutics shares, roughly 23 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trillium Therapeutics.
Find out more about how you can short Trillium Therapeutics stock.
We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.
Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.
Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $5.8 up to $20.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9823. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc.
Steps to owning and managing TCN, with 24-hour and historical pricing before you buy.
Steps to owning and managing NTRB, with 24-hour and historical pricing before you buy.
Steps to owning and managing iPath Series B S&P 500 VIX Short-Term Futures ETN ETF units.
Steps to owning and managing iShares Russell 2000 ETF units.
Steps to owning and managing ProShares UltraPro QQQ ETF units.
Steps to owning and managing ProShares Ultra VIX Short-Term Futures ETF units.
Steps to owning and managing Energy Select Sector SPDR Fund ETF units.
Steps to owning and managing iShares MSCI Emerging Markets ETF units.
Steps to owning and managing Financial Select Sector SPDR Fund ETF units.
Steps to owning and managing SPDR S&P 500 ETF Trust ETF units.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.